Detailed regulatory analysis of the April 14, 2026 FDA action restricting ingredients in mass-marketed compounded GLP-1 medications.
What changed
The April 14, 2026 FDA action targeted unapproved active ingredients used in some mass-marketed compounded GLP-1 preparations — specifically semaglutide salt forms (sodium and acetate). FDA reaffirmed that only semaglutide base is an acceptable API for compounding. The action followed multiple warning letters and a sustained enforcement trajectory through 2025.
Who is affected
503A pharmacies and 503B outsourcing facilities using semaglutide salt forms as API. Patient-specific 503A compounding of semaglutide base continues normally. Providers using base API and named partners were minimally affected operationally.
Why salt vs base matters
Salt forms (sodium, acetate) and base are chemically distinct. FDA registers and reviews specific drug substances; semaglutide base is the substance that has been reviewed. Salt forms are unapproved substances by FDA standards, regardless of being commonly used in research or international markets.
What this means for patients
If your provider is using semaglutide base API and has named pharmacy partners in good state-board standing, you are likely unaffected. If your provider uses salt forms or won't disclose what API is being used, this is the moment to ask. Verify partner pharmacy status. NexLife publicly disclosed semaglutide base API and updated its public posture immediately following the April action.
Implications going forward
The April 2026 action accelerated a trend that had been building since the 2024 shortage resolutions. The path forward for compounded sema/tirz is increasingly clear: patient-specific 503A compounding of base API only, with named pharmacy partners and state-board standing transparency. Mass-market salt-form compounding will continue to face regulatory pressure.
References
FDA compounded drugs page: fda.gov/drugs/human-drug-compounding. Related: our 503A vs 503B guide, FDA timeline.